The Effect of Moxonidine on Blood Pressure and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

Also called NCT01360710

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01360710
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
Not reported
Countries
Australia (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01360710. Randomized; triple masking; primary purpose treatment. Start 2012-01 (registry gives no type); primary completion 2014-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Effect of Moxonidine on Blood Pressure and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension
Condition
Abdominal Obesity
Condition
Hypertension
Intervention (Drug)
Moxonidine
Intervention (Drug)
Irbesartan
Lead sponsor
Baker Heart and Diabetes Institute (class: other)

Record details

Record id
cardio:ct-nct01360710
Content hash
a8a679e71f22b809fd12db37230fddb621abedc75977c3da020c38afed8e7a42